Metabolic properties of freshly isolated bovine endothelial cells

doi:10.1016/0167-4889(83)90084-8

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

Volume 762, Issue 2, 5 April 1983, Pages 295-301

https://doi.org/10.1016/0167-4889(83)90084-8 Get rights and content

Abstract

Studies on endothelial cells metabolism have been limited by the lack of availability of a procedure for obtaining such cells in quantities adequate for direct in vitro analysis. Viable and well-dispersed endothelial cells in high yield have been obtained from the cavernous bodies of bovine penis. A preliminary characterization of the metabolic properties of the isolated cells has concerned the respiratory activity and some aspects of the carbohydrate metabolism. This study points out the following metabolic characteristics of endothelial cells: (1) a low respiration that is inhibited by high glucose concentrations (Crabtree effect); (2) a very high glycolytic activity in aerobic conditions, with a low Pasteur effect; (3) a very high potential activity of the hexose monophosphate shunt relative to the actual flux in the pathway. The biological relevance of these observations is discussed.

References (31)

G.M. Nemecek
Biochim. Biophys. Acta
(1980)
C.C. Haudenschild et al.
J. Ultrastruct. Res.
(1975)
G. Zabucchi et al.
FEBS Lett.
(1975)
F. Rossi et al.
Biochim. Biophys. Acta
(1966)
F. Rossi et al.
Biochim. Biophys. Acta
(1966)
J.S. Hothersall et al.
Arch. Biochem. Biophys.
(1979)
J. Katz et al.
J. Biol. Chem.
(1960)
H.G. Wood et al.
J. Biol. Chem.
(1958)
J.A. Roth et al.
Biochem. Pharmacol.
(1978)
M.A. Trevethick et al.
Biochem. Pharmacol.
(1981)

D. Roos et al.

Blood

(1979)

M.A. Gimbrone

G. Thorgeirsson et al.

Am. J. Pathol.

(1978)

A. Ager et al.

J. Cell. Physiol.

(1982)

G. Cotta-Pereira et al.

J. Cell. Physiol.

(1980)

Cited by (84)

Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1
2020, Cell Metabolism
Citation Excerpt :
Not surprisingly, such a complex specialization process is coordinated by a plethora of signaling factors including paracrine and autocrine factors, shear stress, and even metabolic cues (Carmeliet, 2005b; Gerhardt et al., 2003; Phng and Gerhardt, 2009). Despite the fact that angiogenesis is an energy-consuming process and that ECs have immediate access to blood oxygen, their metabolism is largely glycolytic (Cruys et al., 2016; Dobrina and Rossi, 1983; Krützfeldt et al., 1990), impacting angiogenesis in vivo (Dobrina and Rossi, 1983; Harjes et al., 2012; Harjes et al., 2016; Zecchin et al., 2017). A corollary of the glycolytic nature of EC metabolism is that our knowledge about the role of mitochondria in angiogenesis is scant: angiogenic stimulation increases mitochondrial respiration (Guo et al., 2017) and mitochondria-derived metabolites are essential to fuel cell proliferation and to keep signaling cascades in check.
While endothelial cell (EC) function is influenced by mitochondrial metabolism, the role of mitochondrial dynamics in angiogenesis, the formation of new blood vessels from existing vasculature, is unknown. Here we show that the inner mitochondrial membrane mitochondrial fusion protein optic atrophy 1 (OPA1) is required for angiogenesis. In response to angiogenic stimuli, OPA1 levels rapidly increase to limit nuclear factor kappa-light-chain-enhancer of activated B cell (NFκB) signaling, ultimately allowing angiogenic genes expression and angiogenesis. Endothelial Opa1 is indeed required in an NFκB-dependent pathway essential for developmental and tumor angiogenesis, impacting tumor growth and metastatization. A first-in-class small molecule-specific OPA1 inhibitor confirms that EC Opa1 can be pharmacologically targeted to curtail tumor growth. Our data identify Opa1 as a crucial component of physiological and tumor angiogenesis.
Mitochondrial ATP production provides long-range control of endothelial inositol trisphosphate– evoked calcium signaling
2019, Journal of Biological Chemistry
Citation Excerpt :
Despite the abundant supply of oxygen and mitochondrial substrates, ECs reportedly do not rely on mitochondrial ATP production to meet the cells’ major energy demands. Instead, energy is seemingly derived from glycolysis (1–6). Several proposals may explain why endothelial cells may rely on glycolysis in aerobic conditions (7) (like the Warburg effect in cancer cells (8)).
Endothelial cells are reported to be glycolytic and to minimally rely on mitochondria for ATP generation. Rather than providing energy, mitochondria in endothelial cells may act as signaling organelles that control cytosolic Ca²⁺ signaling or modify reactive oxygen species (ROS). To control Ca²⁺ signaling, these organelles are often observed close to influx and release sites and may be tethered near Ca²⁺ transporters. In this study, we used high-resolution, wide-field fluorescence imaging to investigate the regulation of Ca²⁺ signaling by mitochondria in large numbers of endothelial cells (∼50 per field) in intact arteries from rats. We observed that mitochondria were mostly spherical or short-rod structures and were distributed widely throughout the cytoplasm. The density of these organelles did not increase near contact sites with smooth muscle cells. However, local inositol trisphosphate (IP₃)-mediated Ca²⁺ signaling predominated near these contact sites and required polarized mitochondria. Of note, mitochondrial control of Ca²⁺ signals occurred even when mitochondria were far from Ca²⁺ release sites. Indeed, the endothelial mitochondria were mobile and moved throughout the cytoplasm. Mitochondrial control of Ca²⁺ signaling was mediated by ATP production, which, when reduced by mitochondrial depolarization or ATP synthase inhibition, eliminated local IP₃-mediated Ca²⁺ release events. ROS buffering did not significantly alter local Ca²⁺ release events. These results highlight the importance of mitochondrial ATP production in providing long-range control of endothelial signaling via IP₃-evoked local Ca²⁺ release in intact endothelium.
Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis
2018, Pharmacology and Therapeutics
Citation Excerpt :
As a consequence, most differentiated cells generate ATP using OXPHOS, and glycolysis only becomes the primary ATP source in anaerobic conditions (Vander Heiden, Cantley, & Thompson, 2009). However, in ECs, glycolysis drives the production of >80% of ATP, even in the presence of sufficient oxygen levels for OXPHOS, and ECs are known to be the most glycolytic cells under physiological conditions (Dobrina & Rossi, 1983; Krützfeldt et al., 1990; De Bock, Georgiadou, Schoors et al., 2013). It is estimated that glycolysis flow is 200-fold more than that of mitochondrial OXPHOS and fatty acid oxidation in ECs (Marcu et al., 2017).
Angiogenesis is a complex process describing the growth of new blood vessels from existing vasculature, and is triggered by local pro-angiogenic factors, such as vascular endothelial growth factor (VEGF), which increase the metabolism of endothelial cells (ECs). Angiogenesis takes part in various physiological conditions such as embryogenesis, placental growth, and in pathological conditions such as tumor growth, diabetic retinopathy, rheumatoid arthritis (RA) and ischemic diseases. Current therapies against excessive angiogenesis target vascular growth signaling. However, tumors often counteract these therapies through adaptive mechanisms, thus novel alternative anti-angiogenic strategies are needed. Targeting metabolism is a new anti-angiogenic paradigm, especially through the inhibition of energy metabolism and glycosylation, with the perspective of maintaining the delicate balance between the beneficial and deleterious effects of excessive angiogenesis in patients. Recent studies described a role for EC glycolysis and its main regulator 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in the regulation of angiogenesis, but only few studies are related to the role of the hexosamine biosynthesis pathway during angiogenesis. Glycosylation allows the formation of glycoproteins, glycolipids and proteoglycans and impacts many pathways. The addition of glycans to N-linked proteins is catalyzed by the enzymatic activity of N-acetylglucosaminyltransferases (GnTs), which regulates the glycosylation status of key angiogenic factors such as VEGF receptor 2 (VEGFR2) and Notch. In addition, glycan-galectin (Gal) interactions regulate vascular signaling programs and may contribute to tumor adaptations to anti-angiogenic strategies. Herein, we review novel pharmacological strategies targeting glycosylation, which could be used to decrease excessive angiogenesis in pathological conditions.
Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective
2017, Vascular Pharmacology
Citation Excerpt :
Thus, the PPP has the potential to stimulate biomass production for proliferation or to maintain redox homeostasis [5,64,65]. In many cells, in baseline conditions, only 1–3% of all glucose consumed by the cell is shunted to the PPP [31,66,67]. However, upon oxidative stress, this fraction is increased in order to stimulate G6PDH-dependent NADPH production via the oxPPP [68].
Current anti-angiogenic therapies in malignant and ocular diseases target growth factor signaling in order to attenuate excessive vascular growth. Although initial responses are promising, overall therapeutic success is limited due to insufficient efficiency, tumor refractoriness and resistance. Emerging evidence suggests that diverse growth factor signaling pathways in endothelial cells (ECs) converge onto cellular metabolism, creating an attractive target for novel alternative anti-angiogenic therapies. Recent studies show that ECs rely on glycolysis for ATP and biomass synthesis, necessary for proliferation and migration, key processes of angiogenesis. In addition, fatty acid β-oxidation (FAO) is essential for de novo nucleotide synthesis during EC proliferation. Initial proof-of-evidence has been given that administration of pharmacological inhibitors of those metabolic pathways can be used to inhibit pathological angiogenesis in vivo. Deciphering the role of other metabolic pathways and exploring the therapeutic potential of blocking these pathways await further investigation.
Obesogenic diet disrupts tissue-specific mitochondrial gene signatures in the artery and capillary endothelium
2024, Physiological Genomics
Loss of endothelial cell heterogeneity in arteries after obesogenic diet
2023, bioRxiv

View all citing articles on Scopus

View full text

Metabolic properties of freshly isolated bovine endothelial cells

Abstract

Biochim. Biophys. Acta

J. Ultrastruct. Res.

FEBS Lett.

Biochim. Biophys. Acta

Biochim. Biophys. Acta

Arch. Biochem. Biophys.

J. Biol. Chem.

J. Biol. Chem.

Biochem. Pharmacol.

Biochem. Pharmacol.

Blood

Am. J. Pathol.

J. Cell. Physiol.

J. Cell. Physiol.